Finance | Providing professional financial news & data_第55页

SISRAM MED(01696.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of USD 1.16 million, turned into a loss from a profit YoY

NewTimeSpace News: August 19, 2026, SISRAM MED(01696.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 171.42 million, increased by 3.59% YoY.

NewTimeSpace · 2026-08-20

SISRAM MED 01696.HK turned into a loss from a profit

RECBIO-B(02179.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 211.82 million, loss narrowed by 37.82% YoY

NewTimeSpace News: August 19, 2026, RECBIO-B(02179.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 47 thousand, decreased by 99.57% YoY.

NewTimeSpace · 2026-08-20

RECBIO-B 02179.HK loss narrowed

CHINA BLUECHEM(03983.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 507.45 million, YoY decrease of 20.78%

NewTimeSpace News: August 19, 2026, CHINA BLUECHEM(03983.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 5.62 billion, decreased by 3.95% YoY.

NewTimeSpace · 2026-08-20

CHINA BLUECHEM 03983.HK Profit declined

CH TIANBAO GP(01427.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 64.73 million, loss widened by 73.56% YoY

NewTimeSpace News: August 19, 2026, CH TIANBAO GP(01427.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 368.68 million, decreased by 55.44% YoY.

NewTimeSpace · 2026-08-20

CH TIANBAO GP 01427.HK Loss widens

SOFTCARE(02698.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 75.82 million, YoY increase of 46%

NewTimeSpace News: August 19, 2026, SOFTCARE(02698.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 332.75 million, increased by 30.68% YoY.

NewTimeSpace · 2026-08-20

SOFTCARE 02698.HK profit growth

AIA(01299.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 4.29 billion, YoY increase of 69.46%

NewTimeSpace News: August 20, 2026, AIA(01299.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 11.69 billion, increased by 11.69% YoY.

NewTimeSpace · 2026-08-20

AIA 01299.HK profit

JIUYUAN GENE(02566.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 91.27 million, YoY increase of 1.21%

NewTimeSpace News: August 19, 2026, JIUYUAN GENE(02566.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 630.95 million, decreased by 1.23% YoY.

NewTimeSpace · 2026-08-20

JIUYUAN GENE 02566.HK profit

CMOC(03993.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 16.15 billion, YoY increase of 86.27%

NewTimeSpace News: August 19, 2026, CMOC(03993.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 135.32 billion, increased by 42.78% YoY.

NewTimeSpace · 2026-08-20

CMOC 03993.HK profit growth

LEADS BIOLABS-B (09887.HK): Phase II study abstract of Vimx (opasumivimab) as first-line NSCLC therapy published on WCLC website

NewTimeSpace News: On 20 August 2026, LEADS BIOLABS-B (09887.HK) voluntarily announced that the Phase II study abstract of Vimx™ (a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line NSCLC therapy has been published on the WCLC website, with an ORR of 65.0% and DCR of 95.0% in 60 evaluable patients and an ORR of 77.4% in the squamous subgroup; updated data from follow-up exceeding seven months will be presented orally at WCLC on 14 September.

NewTimeSpace · 2026-08-20

LEADS BIOLABS-B 09887.HK Clinical Progress

GENFLEET-B (02595.HK): two first-in-class pancreatic cancer combination therapies of GFH375 advance to Phase II studies

NewTimeSpace News: On 20 August 2026, GENFLEET-B (02595.HK) voluntarily announced that a three-arm parallel-controlled Phase II study of oral KRAS G12D inhibitor GFH375 has been initiated for patients with previously treated KRAS G12D-mutated pancreatic cancer, including two first-in-class combination regimens (with cachexia bispecific GFS202A and pan-RAS inhibitor GFH276); GFH375 previously obtained breakthrough therapy designation in China and US FDA fast track designation.

NewTimeSpace · 2026-08-20

GENFLEET-B 02595.HK Clinical Trial

CHIHO ENV (00976.HK): files notice of discontinuance, terminating legal proceedings

NewTimeSpace News: On 19 August 2026, CHIHO ENV (00976.HK) voluntarily announced that, following the receivers' sale of the Scholz Group on 31 July 2026, the Company has filed a notice of discontinuance with the High Court of Hong Kong and served it on the defendants, terminating the relevant legal proceedings; the Company's shares remain suspended since 1 April 2025.

NewTimeSpace · 2026-08-20

CHIHO ENV 00976.HK Litigation

GREENTECH INTL (00195.HK): listing cancelled by the Stock Exchange, effective 24 August

NewTimeSpace News: On 19 August 2026, GREENTECH INTL (00195.HK) announced that the Stock Exchange has notified that the last day of listing of its shares will be 21 August 2026, with the listing status cancelled from 9:00 a.m. on 24 August 2026; the Listing Review Committee has upheld the cancellation decision, and the shares will no longer be tradable on the Stock Exchange.

NewTimeSpace · 2026-08-20

GREENTECH INTL 00195.HK Delisting

CTR HOLDINGS (01416.HK): wins bid for land in Kaki Bukit, Singapore for SGD 52.788 million, constituting a very substantial acquisition

NewTimeSpace News: On 19 August 2026, CTR HOLDINGS (01416.HK) announced that its subsidiary Chian Teck has won the bid for land in Kaki Bukit, Singapore at SGD 52.788 million with a 33-year lease; as the applicable percentage ratios exceed 100%, the transaction constitutes a very substantial acquisition subject to EGM approval; the Company plans to build a multi-storey building with 407 dormitory beds and offices at a total cost of approximately SGD 102.79 million.

NewTimeSpace · 2026-08-20

CTR HOLDINGS 01416.HK won the bid

SHOUCHENG (00697.HK): fund invests in Arctic Bear Chip, expanding AI infrastructure and domestic computing power layout

NewTimeSpace News: On 20 August 2026, SHOUCHENG (00697.HK) voluntarily announced that its fund has invested in Arctic Bear Chip Information Technology (Xi'an) Co., Ltd.; Arctic Bear Chip is an AI infrastructure service provider for large model applications with self-developed AI acceleration modules, chiplet and 3DDRAM technologies, and the investment will promote domestic substitution in full-scenario real-time inference.

NewTimeSpace · 2026-08-20

SHOUCHENG 00697.HK Investment

POLY XVERSE IT (00209.HK): Kwok Kin Wai resigns as Independent Non-Executive Director, Ng Ka Yiu appointed

NewTimeSpace News: On 19 August 2026, POLY XVERSE IT (00209.HK) announced that Kwok Kin Wai has resigned as Independent Non-Executive Director and committee member due to other business arrangements, with Ng Ka Yiu appointed in his place, both effective 19 August 2026; Mr. Ng has over 20 years of experience in capital market consulting, audit and tax advisory, with a monthly fee of HKD 10,000.

NewTimeSpace · 2026-08-20

POLY XVERSE IT 00209.HK Board Change

LEADS BIOLABS-B (09887.HK): Oblenio exercises option to retain license for LBL-051, Company to receive USD 10 million

NewTimeSpace News: On 19 August 2026, LEADS BIOLABS-B (09887.HK) voluntarily announced that Oblenio Bio has exercised its option to retain the exclusive global license for LBL-051, with the Company to receive a one-time non-refundable fee of USD 10 million; LBL-051 is an immune reset candidate targeting BCMA, CD19 and CD3 for refractory autoimmune diseases.

NewTimeSpace · 2026-08-20

LEADS BIOLABS-B 09887.HK Clinical Progress